Biphosphonates-associated osteonecrosis of the jaw: Review on reported cases;Les ostéonécroses de la mâchoire associées aux biphosphonates: Synthèse bibliographique

Therapie

Volumn 62, Issue 1, 2007, Pages 49-54

  Gering, Audrey ^a   Grange, Laurent ^a   Villier, Céline ^a   Woeller, Anne ^a   Mallaret, Michel ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Biphosphonates; Jaw; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANTIANGIOGENIC ACTIVITY; AVASCULAR NECROSIS; BONE INJURY; BONE TURNOVER; CANCER CHEMOTHERAPY; CORTICOSTEROID THERAPY; HUMAN; INFECTION; KIDNEY FAILURE; MAXILLA; NEOPLASM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; AGED; ARTICLE; BONE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; JAW DISEASE; MALE; METABOLISM;

AGED; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; OSTEONECROSIS;

EID: 34249752807     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007003     Document Type: Article

References (23)

1. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527-34
2. Agence française de sécurité sanitaire des produits de santé. Lettre aux prescripteurs : acide zolédronique / pamidronate de sodium et ostéonécrose de la mâchoire 7 Juillet 2005 http://agmed.sante.gouv.fr/htm/alertes/indreco.htm
3. FDA. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04- FDA-TAB3.pdf
4. Bagan JV, Muriilo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34(2): 120-3
5. Carter G, Goos AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182(8): 413-5
6. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32(11): 1123-8
7. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117(6): 440-1 [letter]
8. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1): 99-102 [letter]
9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115-7 [letter]
10. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with history of biphosphonate therapy. J Can Dental Assoc 2005; 71(2): 111-3
11. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21(22): 4253-4 [letter]
12. Migliorati CA, Schubert MM, Douglas EP, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104(1): 83-93
13. Najm SA, Lytitsa S, Carrel JP, et al. Ostéonécrose des maxillaires chez des patients traités par biphosphonates. Presse Med 2005; 34: 1073-7
14. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005; 66(3): 658.e1-658e3
15. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005; 182(8): 417-8 [letter]
16. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chimiotherapy. J Oral Maxillofac Surg 2003; 61(9): 1104-1107
17. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw) : is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005; 63(5): 682-9
18. Ott S. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90(3): 1897-9
19. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turn-over by biphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15(4): 613-20
20. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8(5): 1080-4
21. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9(8): 2893-7
22. Thiel HJ. Osteoradionecrosis. I. Etiology, pathogenesis, clinical aspects and risk factors. Radiobiol Radiother 1989; 30(5): 397-413
23. Rosenberg A. Os, articulations et tumeurs des tissus mous. In: Cotran, Kumar et Collins: Anatomie pathologique, tome 2. Padoue: Piccin Nuova, 2000: 1453-87